<DOC>
	<DOCNO>NCT00424541</DOCNO>
	<brief_summary>This study evaluate pharmacokinetic profile , effect rennin inhibition relationship among pharmacokinetics , renin-angiotensin system ( RAS ) biomarkers , blood pressure lower effect oral dos SPP100 Japanese patient mild moderate essential hypertension . Safety also evaluate .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Profiles Aliskiren Japanese Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Japanese patient mild moderate essential hypertension age 20 80 year Blood pressure : Mean ( base 3 recording 12 minute interval ) sit diastolic blood pressure value 14 day 3 day treatment meet follow criterion : 14 day treatment : ≥ 90 mmHg &lt; 110 mmHg 3 day treatment : ≥ 95 mmHg &lt; 110 mmHg The difference mean sit diastolic blood pressure 14 day 3 day treatment within 10 mmHg Body weight less 50 kg Patients mean ( base 3 recording 12 minute interval ) systolic blood pressure ≥ 180 mmHg and/or mean diastolic blood pressure ≥ 110 mmHg Day 28 , Day 14 Day 3 . Patients suspect secondary hypertension Patients suspect malignant hypertension Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Pharmacokinetics , pharmacodynamics , safety , RAS profile , SPP100 , aliskiren , Japanese , essential hypertension</keyword>
	<keyword>Mild moderate essential hypertension</keyword>
</DOC>